secwatch / observer
8-K filed March 19, 2024, 7:59 PM ET ticker CDRE CIK 0001860543
other material confidence high sentiment neutral materiality 0.70

Cadre Holdings raises ~$73.5M in primary offering; CEO's entity sells 1.44M shares

Cadre Holdings, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cadre Holdings, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters (effective 2024-03-14).

Action
entry
Agreement
underwriting
Counterparty
BofA Securities, Inc., as representative of the several underwriters
Effective
2024-03-14
Exact text from the filing
On March 14, 2024, Cadre Holdings, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”), among the Company, Kanders SAF, LLC, a Delaware limited liability company and a stockholder of the Company (the “Selling Stockholder”), and BofA Securities, Inc. (“BofA”), as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the primary public offering (the “Primary Offering”) of 2,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) by the Company and the secondary offering (the “Secondary Offering” and together with the Primary Offering, collectively hereinafter referred to as the “Offering”) of 1,438,127 shares of Common Stock by the Selling Stockholder, at a price to the public of $35.00 per share.
View on SEC.gov

547 material agreements filed in the last 30 days. Browse all material agreements →

Cadre Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-24-036150
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.